CoChat
Sign Up
Cited by 34

The DOI matches its Crossref record.

miR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2

Li, Xiao-Na, Yang, Hong, Yang, Tao·2020·Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
DOI 10.3727/096504019x15615433287579PMC PMC7851573
Open this paper in CoChat — free account

Abstract

In the present study, we investigated the role of miR-122 in hepatocarcinoma progression and explored the mechanism. In hepatocarcinoma tissues and cells, we used qRT-PCR to validate the miR-122 expression level. Next, we used colony formation by crystal violet staining assay to compare cell proliferation ability, and we used scratch test or Transwell assay to compare cell migration or invasion ability. We then conducted bioinformatics or luciferase reporter gene assay to prove the regulation effect of miR-122 on lamin B2 (LMNB2), and the biological function of LMNB2 was analyzed. We used nude mouse tumorigenicity assay to test the inhibition effect of miR-122 ASO therapy against hepatocarcinoma. miR-122 was reduced in hepatocarcinoma tissues compared to the paracarcinoma tissues, which was relatively low or high in hepatocarcinoma cell line SMMC7721 or Hep3B, and overexpressed miR-122 inhibited proliferation, migration, and invasion in hepatocarcinoma cells. Additionally, some reports showed that LMNB2 was regulated by miR-122, which inhibited the expression of LMNB2. Moreover, LMNB2 functioned to promote cell proliferation, migration, and invasion. We could achieve the inhibition of hepatocarcinoma using miR-122 therapy through decreasing LMNB2 expression in vivo. Our data indicated that miR-122 could inhibit hepatocellular carcinoma cell progression by targeting LMNB2 and as a therapeutic target for hepatocarcinoma treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3727/096504019x15615433287579This paper is marked retracted.

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 53

  1. 2017, Cancer statistics, 2017, CA Cancer J Clin., 67, 7, 10.3322/caac.21387 · DOI · Paper page
  2. 2013, miR-122 regulates tumorigenesis in hepatocellular carcinoma by targeting AKT3, PLoS One, 8, e79655, 10.1371/journal.pone.0079655 · DOI
  3. 2017, WNT1 gene from WNT signaling pathway is a direct target of miR-122 in hepatocellular carcinoma, Appl Biochem Biotechnol., 181, 884, 10.1007/s12010-016-2256-8 · DOI
  4. 2016, miR-122-mediated translational repression of PEG10 and its suppression in human hepatocellular carcinoma, J Transl Med., 14, 200, 10.1186/s12967-016-0956-z · DOI
  5. 2016, Targeting PCDH20 gene by microRNA-122 confers 5-FU resistance in hepatic carcinoma, Am J Cancer Res., 6, 1681
  6. 2012, Effects of Kampo medicines on MDR-1-mediated multidrug resistance in human hepatocellular carcinoma HuH-7/PTX cells, Biol Pharm Bull., 35, 1729, 10.1248/bpb.b12-00371 · DOI
  7. 2016, Clinical relevance of circulating cell-free microRNAs in ovarian cancer, Mol Cancer, 15, 48, 10.1186/s12943-016-0536-0 · DOI
  8. 2013, Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer, Cancer Cell, 23, 186, 10.1016/j.ccr.2012.12.020 · DOI
  9. 2004, MicroRNAs: Genomics, biogenesis, mechanism, and function, Cell, 116, 28
  10. 2015, The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer, J Ovarian Res., 8, 23, 10.1186/s13048-015-0143-5 · DOI
  11. 2015, The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells, Mol Oncol., 9, 1678, 10.1016/j.molonc.2015.04.015 · DOI
  12. 2015, Decreased expression of hepatocyte nuclear factor 4alpha (Hnf4alpha)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity, J Biol Chem., 290, 1170, 10.1074/jbc.M114.601203 · DOI
  13. 2015, In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122, Antimicrob Agents Chemother., 59, 599, 10.1128/AAC.04220-14 · DOI
  14. 2010, Antisense gets a grip on miR-122 in chimpanzees, Sci Transl Med., 2, 13ps1
  15. 2009, Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties, Oncogene, 28, 3526, 10.1038/onc.2009.211 · DOI
  16. 2008, miR-122, a paradigm for the role of microRNAs in the liver, J Hepatol., 48, 648, 10.1016/j.jhep.2008.01.019 · DOI
  17. 2016, Artemisia capillaris formula inhibits hepatic steatosis via an miR-122-induced decrease in fatty acid synthase expression in vivo and in vitro, Mol Med Rep., 13, 4751, 10.3892/mmr.2016.5131 · DOI
  18. 2008, miR-122 targets an anti-apoptotic gene Bcl-w, in human hepatocellular carcinoma cell lines, Biochem Biophys Res Commun., 375, 315, 10.1016/j.bbrc.2008.07.154 · DOI
  19. 2009, Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy, Nat Med., 15, 31, 10.1038/nm.1902 · DOI
  20. 2009, MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma, Hepatology, 49, 1571, 10.1002/hep.22806 · DOI
  21. 2009, miR-122 affects the viability and apoptosis of hepatocellular carcinoma cells, Scand J Gastroenterol., 44, 1332, 10.3109/00365520903215305 · DOI
  22. 2015, The miR-193a-3p-regulated LMNB2 gene activates the DNA damage response pathway and inhibits multi-chemo-resistance in bladder cancer, Oncotarget, 6, 10195, 10.18632/oncotarget.3555 · DOI
  23. 2001, Single-nucleotide polymorphisms of the nuclear lamina proteome, J Hum Genet., 46, 351, 10.1007/s100380170072 · DOI
  24. 2017, Induction of retinal-dependent calcium influx in human melanocytes by UVA or UVB radiation contributes to the stimulation of melanosome transfer, Cell Prolif., 50
  25. 2014, MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells, J Cell Biochem., 115, 772, 10.1002/jcb.24721 · DOI
  26. 2015, MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1, J Ovarian Res., 8, 80, 10.1186/s13048-015-0207-6 · DOI
  27. 2015, miR-122 is a unique molecule with great potential in diagnosis, prognosis of liver disease, and therapy both as miRNA mimic and antimir, Curr Gene Ther., 15, 142, 10.2174/1566523214666141224095610 · DOI
  28. 2009, Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties, Oncogene, 28, 3526, 10.1038/onc.2009.211 · DOI
  29. 2010, Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development, Hepatology, 52, 1431, 10.1002/hep.23818 · DOI
  30. 2012, A feedback loop between the liver-enriched transcription factor network and miR-122 controls hepatocyte differentiation, Gastroenterology, 142, 119, 10.1053/j.gastro.2011.09.001 · DOI
  31. 2017, Crosstalk between microRNA-122 and FOX family genes in SMMC7721 cells, Exp Biol Med. (Maywood), 242, 436, 10.1177/1535370216681548 · DOI
  32. 2009, MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib, J Biol Chem., 284, 32015, 10.1074/jbc.M109.016774 · DOI
  33. 2016, MiR-122 reverses the doxorubicin-resistance in hepatocellular carcinoma cells through regulating the tumor metabolism, PLoS One, 11, e0152090, 10.1371/journal.pone.0152090 · DOI
  34. 2016, MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways, Cancer Lett., 371, 171, 10.1016/j.canlet.2015.11.034 · DOI · Paper page
  35. 2011, MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest, Cancer Lett., 310, 160
  36. 2015, The effects of multifunctional MiR-122-loaded graphene–gold composites on drug-resistant liver cancer, J Nanobiotechnology, 13, 12, 10.1186/s12951-015-0070-z · DOI
  37. 2015, Ultrasound-guided delivery of microRNA loaded nanoparticles into cancer, J Control Release, 203, 99, 10.1016/j.jconrel.2015.02.018 · DOI
  38. 2018, Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma, J Cancer Res Clin Oncol., 144, 205, 10.1007/s00432-017-2543-y · DOI
  39. 2017, MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression, J Ovarian Res., 10, 1, 10.1186/s13048-016-0301-4 · DOI
  40. 2017, Circulating miRNAs as novel diagnostic biomarkers in hepatocellular carcinoma detection: A meta-analysis based on 24 articles, Oncotarget, 8, 66402, 10.18632/oncotarget.18949 · DOI
  41. 2017, Lamin B2 binding to minichromosome maintenance complex component 7 promotes non-small cell lung carcinogenesis, Oncotarget, 8, 104813, 10.18632/oncotarget.20338 · DOI
  42. 2015, Quantitative proteomic analysis of the metastasis-inhibitory mechanism of miR-193a-3p in non-small cell lung cancer, Cell Physiol Biochem., 35, 1677, 10.1159/000373981 · DOI
  43. 2015, Mutation of the nuclear lamin gene LMNB2 in progressive myoclonus epilepsy with early ataxia, Hum Mol Genet., 24, 4483, 10.1093/hmg/ddv171 · DOI
  44. 2016, The RNA-binding protein SFPQ orchestrates an RNA regulon to promote axon viability, Nat Neurosci., 19, 690, 10.1038/nn.4280 · DOI
  45. 2017, Low lamin A expression in lung adenocarcinoma cells from pleural effusions is a pejorative factor associated with high number of metastatic sites and poor performance status, PLoS One, 12, e0183136, 10.1371/journal.pone.0183136 · DOI
  46. 2003, Neuroblastoma: Biological insights into a clinical enigma, Nat Rev Cancer., 3, 203, 10.1038/nrc1014 · DOI
  47. 2012, Chromosomal regions associated with prostate cancer risk localize to lamin B-deficient microdomains and exhibit reduced gene transcription, J Pathol., 226, 735, 10.1002/path.3033 · DOI
  48. 2012, Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway, Carcinogenesis, 33, 751, 10.1093/carcin/bgs022 · DOI
  49. 2012, Discovery of lamin B1 and vimentin as circulating biomarkers for early hepatocellular carcinoma, Methods Mol Biol., 909, 295
  50. 2013, The clinicopathological significance of lamin A/C, lamin B1 and lamin B receptor mRNA expression in human breast cancer, Cell Mol Biol Lett., 18, 595
  51. 2017, Prognostic role of NF-YA splicing isoforms and lamin A status in low grade endometrial cancer, Oncotarget, 8, 7935, 10.18632/oncotarget.13854 · DOI
  52. 2015, Differential predictive roles of A- and B-type nuclear lamins in prostate cancer progression, PLoS One, 10, e0140671, 10.1371/journal.pone.0140671 · DOI
  53. 2016, A novel role of lamins from genetic disease to cancer biomarkers, Oncol Rev., 10, 309

Cited by

Sorted by citations

Metadata

Authors
Li, X.-N., Yang, H., & Yang, T.
Venue
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
Publisher
Tech Science Press
Published
2020-02-07
Volume
28
Issue
1
Pages
41-49
ISSN
0965-0407
DOI
10.3727/096504019x15615433287579
PMC
PMC7851573
Cited by
34
References
0
Language
en
Status
Retracted
Update notices
retraction (2026-04-22)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review